Glenmark Pharmaceuticals has said that it has got final approval from the US health regulator for its generic version of AstraZeneca’s Xylocaine ointment.

The company has said in a statement that the approval given by the US Food & Drug Administration (USFDA) to Glenmark Pharmaceuticals Inc USA (Glenmark) is for Lidocaine Ointment USP, 5 percent.

Glenmark has said that in addition to these internal filings it has been continuing to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Read EquityPandit’s Nifty Pharma Outlook for this week